How Analysts Feel About Precigen Inc. (PGEN)?

As of Wednesday close, Precigen Inc.’s (NASDAQ:PGEN) stock was down -$0.02, moving down -0.98 percent to $1.51. The average number of shares traded per day over the past five days has been 4,016,860 shares. 2 times new highs have been achieved over the past 5 days, with a $0.2750 gain in that time frame. In the last twenty days, the average volume was 1,842,520, while in the previous 50 days, it was 1,553,290.

Since last month, PGEN stock rose 11.40%. Shares of the company fell to $1.0600 on 08/07/23, the lowest level in the past month. A 52-week high of $2.90 was reached on 01/23/23 after having rallying from a 52-week low of $0.81. Since the beginning of this year, PGEN’s stock price has dropped by -0.33% or -$0.0050, and marked a new high 10 times. However, the stock has declined by -47.76% since its 52-week high.

PGEN stock investors should be aware that Precigen Inc. (PGEN) stock had its last reported insider trading activity 3 days ago on Aug 14. Hassan Fred, the Director of the company, purchased of 570,345 shares for $1.75 on Aug 14. It resulted in a $998,104 investment by the insider. Frank Steven added 400,000 shares at an average price of $1.72 on Aug 14. The insider now owns 882,358 shares following the transaction. On Aug 11, President and CEO Sabzevari Helen sold 41,436 shares at $1.44 apiece. The transaction was valued at $59,668.

Valuation Metrics

The stock’s beta is 1.89. Besides these, the trailing price-to-sales (P/S) ratio of 16.47, the price-to-book (PB) ratio of 1.89.

Financial Health

On the profitability front, the trailing twelve-month gross margin is 73.50% percent. Based on annual data, PGEN earned $20.57 million in gross profit and brought in $26.91 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -44.60%. Return on equity (ROE) for the past 12 months was 22.30%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PGEN’s revenue fell -64.41% to $1.85 million during the quarter, while net income inched up to $1.77 million. While analysts expected Precigen Inc. to report -$0.1 quarterly earnings, the actual figure was -$0.08 per share. During the quarter, the company generated -$19.92 million in EBITDA. The liabilities of Precigen Inc. were 41.32 million at the end of its most recent quarter ended June 29, and its total debt was $7.97 million. The value of shareholders’ equity is $255.48 million.

Technical Picture

This quick technical analysis looks at Precigen Inc.’s (PGEN) price momentum. With a historical volatility rate of 114.36%, the RSI 9-day stood at 62.45% on 16 August.

With respect to its five-day moving average, the current Precigen Inc. price is up by +22.18% percent or $0.2750. At present, PGEN shares trade +7.45% above its 20-day simple moving average and +61.65% percent above its 100-day simple moving average. However, the stock is currently trading approximately +13.06% above its SMA50 and -3.50% below its SMA200.

Stochastic coefficient K was 67.33% and Stochastic coefficient D was 75.19%, while ATR was 0.1671. Given the Stochastic reading of 60.26% for the 14-day period, the RSI (14) reading has been calculated as 61.04%. As of today, the MACD Oscillator reading stands at 0.1889, while the 14-day reading stands at 0.2258.

Analyst Ratings

JP Morgan launched its rating on Precigen Inc. (NASDAQ: PGEN) to a Neutral in a note to investors on May 23, 2023. Precigen Inc. (PGEN) has been rated Buy by analysts. According to 0 brokerage firms, PGEN is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Precigen Inc. stock as buy, with 4 recommending it as overweight.

With a median target price of $9.00, the current consensus forecast for the stock is $6.00 – $14.00. Based on these forecasts, analysts predict Precigen Inc. (PGEN) will achieve an average price target of $9.50.

Most Popular

Related Posts